Tarsus Pharmaceuticals Announces Initiation of Phase 2a Trial of Lyme Disease Prevention Therapeutic
As reported on WDRB.com on November 9, 2022, from Tarsus Pharmaceuticals, Inc. (GLOBAL NEWSWIRE) Tarsus “is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial.”
According to https://tarsusrx.com/pipeline/tp-05/, Tarsus indicates it believes TP-05 is “the only non-vaccine drug-based preventive therapeutic in development that targets and kills infected tick vectors before they can kill Borrelia burgdorferi….” This formula provides rapid systemic blood levels of lotilaner, an anti-parasitic agent.
Further information on TP-05 from the company indicates it also has the potential to cause death of mosquitoes that transmit malaria.
For more information